Formation of a Novel C11-Acetone Adduct of a Pyrrolobenzodiazepine (PBD) with Loss of Cytotoxicity

Abstract

The pyrrolidine-catalysed formation of novel diastereomeric C11-acetone adducts was observed during the chromatographic purification of pyrrolobenzodiazepine (PBD) compounds in the presence of acetone. The mechanism of this reaction was explored and the adducts obtained fully characterised. Talirine, the cytotoxic payload element of the antibody-drug conjugate (ADC) vadastuximab talirine, was also found to form a bis-adduct under similar conditions. A cellular cytotoxicity evaluation of the modified PBD compounds confirmed their lack of cytotoxicity, consistent with loss of the DNA-interactive N10–C11 imine functionality. As well as the new chemistry reported here, given the number of PBD-based ADCs presently in the clinic, this observation may be important for the larger-scale manufacture of PBD-based products.

Key words

pyrrolobenzodiazepines - PBDs - Stork enamine - DNA-binding, Talirine, ADC.

• References

• 1 Gerratana B. Med. Res. Rev. 2012; 32: 254
• 2 Gregson SJ. Howard PW. Hartley JA. Brooks NA. Adams LJ. Jenkins TC. Kelland LR. Thurston DE. J. Med. Chem. 2001; 44: 737
• 3 Mellinas-Gomez M. Spanswick VJ. Paredes-Moscosso SR. Robson M. Pedley RB. Thurston DE. Baines SJ. Stell A. Hartley JA. BMC Vet. Res. 2015; 11: 215
• 4 Beck A. Goetsch L. Dumontet C. Corvaia N. Nat. Rev. Drug Discovery 2017; 315
• 5 Mantaj J. Jackson PJ. Rahman KM. Thurston DE. Angew. Chem. Int. Ed. 2017; 56: 462
• 6 Stein AS. Walter RB. Erba HP. Fathi AT. Advani AS. Lancet JE. Ravandi F. Kovacsovics TJ. DeAngelo DJ. Bixby D. Blood 2015; 126: 324
• 7 Rahman KM. James CH. Bui TT. T. Drake AF. Thurston DE. J. Am. Chem. Soc. 2011; 133: 19376
• 8 Rahman KM. Mussa V. Narayanaswamy M. James CH. Howard PW. Thurston DE. Chem. Commun. 2009; 2: 227
• 9 Rahman KM. Thompson AS. James CH. Narayanaswamy M. Thurston DE. J. Am. Chem. Soc. 2009; 131: 13756
• 10 Rahman KM. Thurston DE. Chem. Commun. 2009; 20: 2875
• 11 Puvvada MS. Forrow SA. Hartley JA. Stephenson P. Gibson I. Jenkins TC. Thurston DE. Biochemistry 1997; 36: 2478
• 12 Puvvada MS. Hartley JA. Jenkins TC. Thurston DE. Nucleic Acids Res. 1993; 21: 3671
• 13 Kotecha M. Kluza J. Wells G. O'Hare CC. Forni C. Mantovani R. Howard PW. Morris P. Thurston DE. Hartley JA. Mol. Cancer Ther. 2008; 7: 1319
• 14 Rahman KM. Jackson PJ. M. James CH. Basu BP. Hartley JA. De La Fuente M. Schatzlein A. Robson M. Pedley RB. Pepper C. Fox KR. Howard PW. Thurston DE. J. Med. Chem. 2013; 56: 2911
• 15 Antonow D. Thurston DE. Chem. Rev. 2010; 111: 2815
• 16 Dornisch E. Pletz J. Glabonjat RA. Martin F. Lembacher-Fadum C. Neger M. Hoegenauer C. Francesconi K. Kroutil W. Zangger K. Breinbauer R. Zechner EL. Angew. Chem. Int. Ed. 2017; 56: 14753
• 17 Adiyala PR. Tekumalla V. Sayeed IB. Nayak VL. Nagarajan A. Shareef MA. Nagaraju B. Kamal A. Bioorg. Chem. 2018; 76: 288
• 18 Dragovich PS. Broccatelli F. Chen J. Fan P. Le H. Mao W. Pillow TH. Polson AG. Wai J. Xu Z. Bioorg. Med. Chem. Lett. 2017; 27: 5300
• 19 Tiberghien AC. Levy J.-N. Masterson LA. Patel NV. Adams LR. Corbett S. Williams DG. Hartley JA. Howard PW. ACS Med. Chem. Lett. 2016; 7: 983
• 20 Morris SJ. Thurston DE. Nevell TG. J. Antibiot. 1990; 43: 1286
• 21 Zioga G. Howard PW. Canfield LM. Gescher A. Thurston DE. Pharm. Sci. 1996; 2: 39
• 22 Mori S. Ohno T. Harada H. Aoyama T. Shioiri T. Tetrahedron 1991; 47: 5051
• 23 Schneditz G. Rentner J. Roier S. Pletz J. Herzog KA. T. Bücker R. Troeger H. Schild S. Weber H. Breinbauer R. Proc. Natl. Acad. Sci. U.S.A. 2014; 111: 13181
• 24 Shioiri T. Aoyama T. Yamagami N. Shimizu N. Mori N. Kohda K. Anti-Cancer Drug Des. 1995; 10: 167
• 25 Kohda K. Yamagami N. Kasamatsu T. Aoyama T. Shioiri T. Biochem. Pharmacol. 1995; 49: 1063
• 26 Experimental procedure for the synthesis of 16 and 17. Pyrrolidine (2.3 µL, 0.1 equiv) was added to a solution of 10 (100 mg, 1 equiv) in acetone (1 mL), and the solution allowed to stir at room temperature for 72 hours. The excess acetone and pyrrolidine were removed under reduced pressure, and the resulting oil purified using flash column chromatography (20:80 acetone/dichloromethane) to resolve the two diastereomers 16 and 17 (both yellow oils) in ~67% overall yield. Methyl 4-(((11S,11aS)-7-methoxy-5-oxo-11-(2-oxopropyl)-2,3,5,10,11,11a-hexahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)butanoate (16; Major Diastereomer): ¹HNMR (400 MHz, CDCl₃): 7.29 (s, 1 H), 6.19 (s, 1 H), 4.02 (t, 2 H, J = 6.2 Hz), 3.84 (s, 3 H), 3.79–3.66 (m, 2 H), 3.70 (s, 3 H), 3.69–3.65 (m, 1 H), 3.44 (ddd, 1 H, J = 10.6, 8.9, 4.9 Hz), 2.57–2.52 (m, 4 H), 2.24 (s, 3 H) 2.19–2.07 (m, 2 H), 2.05–1.92 (m, 3 H), 1.75–1.64 (m, 1 H). ¹³CNMR (100 MHz, CDCl₃): 208.3, 173.6, 168.4, 151.2, 144.6, 138.3, 119.4, 113.1, 106.7, 67.8, 61.7, 60.0, 56.2, 53.7, 51.7, 46.9, 30.8, 30.3, 30.0. 24.7, 23.2. Methyl 4-(((11R,11aS)-7-methoxy-5-oxo-11-(2-oxopropyl)-2,3,5,10,11,11a-hexahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)butanoate (17, Minor Diastereomer): ¹HNMR (400 MHz, CDCl₃): 7.45 (s, 1 H), 5.97 (s, 1 H), 4.05–3.99 (m, 2 H), 3.95 (t, 2 H, J = 6.3 Hz), 3.92–3.85 (m, 1 H), 3.77 (s, 3 H), 3.64 (s, 3 H), 3.61–3.52 (m, 1 H), 2.79 (dd, 1 H, J = 18.0, 10.4 Hz), 2.51–2.44 (m, 3 H), 2.29–2.18 (dt, 1 H, J = 13.2, 7.2 Hz) 2.15–2.04 (m, 5 H), 1.93–1.80 (m, 2 H), 1.72–1.61 (m, 1 H).
• 27 Kempf B. Hampel N. Ofial AR. Mayr H. Chem. Eur. J. 2003; 9: 2209
• 28 Jeffrey SC. Burke PJ. Lyon RP. Meyer DW. Sussman D. Anderson M. Hunter JH. Leiske CI. Miyamoto JB. Nicholas ND. Bioconjugate Chem. 2013; 24: 1256